Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
About Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, molecularly-targeted, small-molecule therapies to address serious diseases, including oncology, obesity, and chronic liver diseases. Headquartered in Foster City, California, with additional operations in Shanghai, the company combines its expertise in medicinal chemistry and disease biology with a capital-efficient drug discovery model to advance its robust pipeline of therapeutic candidates.
The company's focus on small-molecule therapies enables the development of orally administered drugs, offering potential advantages in terms of patient convenience, scalability, and cost-effectiveness compared to injectable biologics. Terns’ pipeline includes multiple clinical-stage programs targeting significant unmet medical needs:
- TERN-701: An oral, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) in development for chronic myeloid leukemia (CML). This novel therapy aims to overcome the limitations of traditional active-site TKIs, offering improved efficacy and safety profiles.
- TERN-601: A small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist designed for the treatment of obesity. This candidate demonstrates promising weight loss efficacy and a favorable tolerability profile, addressing common challenges associated with GLP-1 therapies.
- TERN-501: A thyroid hormone receptor-beta (THR-β) agonist targeting non-alcoholic steatohepatitis (NASH) and other liver diseases.
- TERN-800 Series: A preclinical program focused on glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for metabolic disorders.
Terns Pharmaceuticals operates within competitive and innovation-driven markets, where its focus on clinically validated targets and its ability to develop differentiated small-molecule therapies position it as a key player. The company’s strategic emphasis on both oncology and metabolic diseases reflects its commitment to addressing substantial unmet medical needs globally.
By leveraging its dual presence in the United States and China, Terns benefits from access to diverse patient populations, streamlined clinical development capabilities, and cost efficiencies. Its capital-efficient drug discovery model further supports the advancement of its pipeline while mitigating financial risks inherent to clinical-stage companies.
As a clinical-stage company, Terns Pharmaceuticals is reliant on the success of its ongoing and future clinical trials. Its ability to secure regulatory approvals and navigate competitive landscapes will be critical to its long-term success. However, its strong pipeline, innovative approach to drug development, and focus on addressing unmet medical needs provide a solid foundation for potential growth.
FOSTER CITY, Calif., March 21, 2022 – Terns Pharmaceuticals (Nasdaq: TERN) announced top-line results from Part 1 of the Phase 1b AVIATION Trial for TERN-201, a VAP-1 inhibitor aimed at treating non-alcoholic steatohepatitis (NASH). Part 1 met the primary safety endpoint, showing TERN-201 was well-tolerated with mild to moderate adverse events, but did not demonstrate significant changes in NASH biomarkers compared to placebo. Part 2 of the trial with a higher dose is ongoing, with results expected in H2 2022. Terns maintains a cash runway into 2024 and plans further trials for other candidates.
Terns Pharmaceuticals, Inc. reported significant developments in its clinical pipeline and financial results for 2021. Expected top-line data from TERN-201's NASH trial will be released in March 2022, while TERN-501 will begin its first NASH trial in H1 2022, with results anticipated in H2 2023. The company holds $166 million in cash, providing funding into 2024. R&D expenses rose to $31.3 million, contributing to a net loss of $50.2 million for the year. Despite these losses, Terns' leadership changes and pipeline advancements position it for future growth, focusing on serious diseases like NASH and obesity.
Terns Pharmaceuticals (Nasdaq: TERN) announced its participation in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 12:50 PM ET. The event will address serious diseases, including NASH and obesity, which are central to Terns' clinical focus. A live webcast will be accessible on Terns' investor relations page, with a replay available for 30 days post-presentation. The company is advancing a pipeline featuring small-molecule therapies and combination treatments aimed at improving patient outcomes.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced the appointment of Jeffrey R. Jasper, Ph.D., as Senior Vice President and Head of Research, and the promotion of Diana Chung to Senior Vice President and Chief Development Officer. Dr. Jasper brings over 28 years of industry experience, having held key roles at Rubedo Life Sciences and Merck. Chung has over 20 years of experience in drug discovery and clinical development. Terns aims to advance its pipeline towards a combination trial for NASH in 2022, leveraging the expertise of its strengthened leadership team.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on serious diseases like non-alcoholic steatohepatitis (NASH), will showcase its progress at upcoming investor conferences. The key events are the 40th Annual J.P. Morgan Health Care Conference on January 13, 2022, at 11:15 a.m. ET, and the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10, 2022, at 7:00 a.m. ET. Interested parties can access live audio webcasts and replays on Terns' investor relations website.
Terns Pharmaceuticals reported strong progress in its clinical pipeline and financial health for Q3 2021, with cash reserves of $177 million projected to sustain operations into 2024. The company announced positive top-line data from TERN-501 supporting its role as a promising THR-β agonist in treating non-alcoholic steatohepatitis (NASH), and is set to initiate new trials in 1H 2022. The third quarter net loss was $11.8 million, slightly higher than the previous year, but R&D expenses rose to $7.2 million aimed at advancing its clinical candidates.
Terns Pharmaceuticals announced positive results from the Phase 2a LIFT Trial of TERN-101, demonstrating significant decreases in cT1, a marker of liver inflammation and fibrosis, over 12 weeks of treatment. The trial showed TERN-101 to be safe and well-tolerated, correlating cT1 improvements with reduced clinical event risks. Additionally, Phase 1 data for TERN-501 indicated well-tolerated single doses leading to significant LDL decreases and SHBG increases, pointing to its potential efficacy in treating NASH. Both compounds are pivotal in Terns' NASH treatment strategy.
Terns Pharmaceuticals reported positive Phase 1 clinical trial results for TERN-501, a THR-β agonist targeting non-alcoholic steatohepatitis (NASH). The trial showed that TERN-501 was generally safe, well-tolerated, and demonstrated favorable pharmacokinetic properties with a half-life of over 13 hours. Significant reductions in LDL cholesterol of up to 28% and marked increases in sex hormone binding globulin were observed. Terns plans to initiate an FXR/THR-β agonist combination trial in NASH in the first half of 2022.
On October 18, 2021, Terns Pharmaceuticals announced three accepted abstracts for presentation at The Liver Meeting® Digital Experience 2021, focusing on their non-alcoholic steatohepatitis (NASH) programs. Key presentations include:
- TERN-101: Favorable safety and efficacy from the Phase 2a LIFT Study.
- TERN-501: Well-tolerated in first-in-human trials, showing dose-dependent cholesterol changes.
These findings underscore Terns' commitment to developing effective therapies for chronic liver diseases.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 5th Annual NASH Investor Conference set for October 12, 2021, at 2:30 p.m. ET. The company is focused on developing therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases, featuring a portfolio that includes three clinical-stage programs and a preclinical program. A live audio webcast of the presentation will be available on Terns’ investor relations page, with a replay archived for 30 days.
FAQ
What is the current stock price of Terns Pharmaceuticals (TERN)?
What is the market cap of Terns Pharmaceuticals (TERN)?
What does Terns Pharmaceuticals specialize in?
What is TERN-701?
How does Terns Pharmaceuticals differentiate itself in the biopharmaceutical industry?
What is the significance of TERN-601?
Where is Terns Pharmaceuticals headquartered?
What is the TERN-800 series?
What are the key therapeutic areas Terns Pharmaceuticals is targeting?
What is the company’s approach to drug development?
What challenges does Terns Pharmaceuticals face as a clinical-stage company?
How does Terns Pharmaceuticals leverage its dual presence in the U.S. and China?
